✦ LIBER ✦

Inhibition of ascites tumor growth in vivo by sTie-2 is potentiated by a combinatorial therapy with sFLT-1

✍ Scribed by Saritha Sandra D'Souza; Anupama E. Gururaj; Harsha M. Raj; Jochen Rössler; Bharathi P. Salimath

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 494 KB
Volume: 12
Category: Article
ISSN: 1099-498X
DOI: 10.1002/jgm.1520

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

Inhibition of tumor angiogenesis is a promising approach for cancer therapy and the Tie‐2/angiopoietin pathway appears to play an important role. In the present study, we have developed strategies to explore the therapeutic potential of blocking the Tie‐2/angiopoietin pathway by sTie‐2.

Methods

Ehrlich ascites tumor (EAT) cells were stably transfected to overexpress a truncated form of sTie‐2. Transfectants were characterized for their in vitro growth behavior and transplanted into nude mice. Furthermore, recombinant sTie‐2 produced by the baculovirus expression system was used to sequester angiopoietins in the murine ascites carcinoma model. The effect of sTie‐2 treatment alone or in combination with sFLT‐1 on the weight of the animal, ascites cell number and volume was studied.

Results

EAT cells stably transfected with a truncated form of sTie‐2 showed no change in cell proliferation in vitro and colony forming in soft agar compared to control cells. However, sTie‐2 transfected EAT cells transplanted into nude mice reduced tumor burden and demonstrated a reduction in ascites formation and peritoneal angiogenesis. Recombinant sTie‐2 showed angiogenic activity in the tube formation and wound healing assay in vitro. sTie‐2 treatment alone or in combination with sFLT‐1 in an ascites tumor mouse model resulted in reduced peritoneal angiogenesis, with a concomitant decrease in tumor cell number, volume of ascites and the number of invasive tumor cells, as assayed by CD31 staining.

Conclusions

The findings of the present study demonstrate an important role for the Tie‐2/angiopoietin pathway in the formation of tumor vasculature and suggest that sTie‐2 might yield useful anticancer therapy. Copyright © 2010 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Paracrine action of sFLT-1 secreted by s

Paracrine action of sFLT-1 secreted by stably-transfected Ehrlich ascites tumor cells and therapy using sFLT-1 inhibits ascites tumor growth in vivo

✍ Sunitha Ramachandra; Saritha Sandra D'Souza; Anupama E. Gururaj; Melkote S. Shai 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 441 KB 👁 1 views

## Abstract ## Background Vascular endothelial growth factor (VEGF) is known to play a major role in angiogenesis. A soluble form of Flt‐1, a VEGF receptor, is potentially useful as an antagonist of VEGF, and accumulating evidence suggests the applicability of sFlt‐1 in tumor suppression. In the p

cAMP-mediated growth inhibition of a B-l

cAMP-mediated growth inhibition of a B-lymphoid precursor cell line Reh is associated with an early transient delay in G2/M, followed by an accumulation of cells in G1

✍ Heidi Kiil Blomhoff; Rune Blomhoff; Trond Stokke; Catharina DeLange Davies; Kris 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 491 KB 👁 1 views

This study was undertaken to gain more insight into the effects of cyclic adenosine monophosphate (cAMP) on cell-cycle progression in the B-lymphoid precursor cell line Reh. The adenylate cyclase activator forskolin reduced the proliferation of asynchronously growing Reh cells by 50% after 72 hr cul